A forum for researchers, students and applicants in the field of cyclodextrin technology
Acute myeloid leukaemia (AML), accounts for 30 % of adult leukaemia cases, predominantly affects individuals over 60. The standard “7 + 3” intensive
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
In the laboratory of C. M. O’Driscoll (University College Cork), an antibody targeted cyclodextrin-based siRNA delivery vector (CD.DSPE-PEGFab) was developed
